NCT07724886 Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
| NCT ID | NCT07724886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Bladder Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 732 participants |
| Start Date | 2026-10-19 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 732 participants in total. It began in 2026-10-19 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or above * Fulfil any one of the following three criteria: 1. Recurrent bladder tumour 2. Multiple bladder tumours 3. Any bladder tumour size of \>1cm Exclusion Criteria: * EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5) * EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5) * Any prior use of intravesical BCG therapy * Presence or prior history of upper urinary tract malignancy * Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16) * Presence of GOLD Stage III or IV chronic obstructive pulmonary disease * ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18) * History of bleeding disorder or use of anti-coagulants * Pregnancy * Presence of other active malignancy
Contact & Investigator
Yuen Chun Jeremy TEOH, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT07724886 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07724886 currently recruiting?
Yes, NCT07724886 is actively recruiting participants. Contact the research team at jeremyteoh@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT07724886 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Sheung Shui, Hong Kong.
Who is sponsoring the NCT07724886 clinical trial?
NCT07724886 is sponsored by Chinese University of Hong Kong. The principal investigator is Yuen Chun Jeremy TEOH, MD at Chinese University of Hong Kong. The trial plans to enroll 732 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.